The FDA will soon add 10 drug inspectors to its office in China to help oversee that country's vast API and drug production industry. If the FDA's experience in India is an indicator, it will mean a raft of enforcement actions in a country that is considered to have weak enforcement by its own agency.
Biomarker testing can play in an important role in detecting cancer early and choosing the correct course of treatment, and it can be critical in dealing with deadly, fast-spreading diseases like lung cancer. China has keyed into its utility, with non-small cell lung cancer (NSCLC) biomarker testing already prevalent throughout the country, a new report says.
U.K. Prime Minister David Cameron thinks GlaxoSmithKline is a "very decent and strong British business" and has been talking it up with Chinese officials during his trade visit there.
GlaxoSmithKline CEO Andrew Witty is on his first trip to China since authorities there alleged his company funneled $490 million in bribes to doctors. Despite the scandal, GSK says it remains committed to doing business in China.
Morrisville, NC-based Gentris is setting up a new genomic biomarker testing service in Shanghai, a growing global hub for drug development.
China is a big, climatologically-diverse country, with the weather changing significantly between the temperate zones in the north and the subtropical regions further south. This affects when flu seasons occur, and consequently when health authorities should run vaccination campaigns.
Qiagen won Chinese regulatory approval for a next-generation tuberculosis test and expects a commercial rollout there in the early part of 2014.
Johnson & Johnson's Janssen unit and Merck KGaA are joining the parade of companies rolling out new manufacturing facilities in China, a market that could become the world's largest in a decade.
Catalent's new clinical supply operation in Shanghai is now open for business, giving the company a 31,000-square-foot operation it said offers broader capabilities than anything else in China.
The investigation by Chinese authorities into of a host of drugmakers for bribery has put a chill on business there, but not frozen them in their tracks. Plans announced in the last two days by Johnson & Johnson and Merck KGaA to build new plants in China shows the market is too vast and too important to allow a little uncertainty to put plans on ice.